NVO gains ground in the GLP-1 battle as Ozempic outshines Trulicity in heart risk reduction and Rybelsus wins EU approval for ...

In a rodent model of T2D, icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with ...

In a rodent model of T2D, icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with preservation of lean mass, outperforming the group given ...

Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients lose weight more effectively and stay on track with its flagship medication, Wegovy ...

Researchers in Denmark observed a significant drop-off in anti-obesity drug usage after 1 year in first-time users.

Researchers have found bariatric surgery to be more cost-effective for treating patients with obesity compared with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), according to new study ...

Each one-unit increase in postsurgical BMI was associated with an 8% increased likelihood of GLP-1RA initiation.

Maintaining weight loss with regular exercise rather than the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide, ...

Fourteen percent of individuals initiate glucagon-like peptide 1 receptor agonists (GLP-1 RAs) after bariatric surgery, according to a study published online Aug. 27 in JAMA Surgery. Minji Kim, ...

Female patients, those undergoing sleeve gastrectomy, and those with type 2 diabetes were more likely to initiate GLP-1 RAs. (HealthDay News) — Fourteen percent of individuals initiate glucagon-like ...

(NEXSTAR) – Patients using Ozempic and other GLP-1 drugs are reporting a complication not listed among the drug’s most common side effects. (We’re not talking about “Ozempic babies,” but that’s also a ...